Format

Send to

Choose Destination
Blood. 2015 Jun 4;125(23):3668-9. doi: 10.1182/blood-2015-03-635391.

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

Author information

1
Division of Hematology, Brigham and Women's Hospital, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
2
Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
3
Division of Hematology, Brigham and Women's Hospital, Boston, MA.
4
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
5
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA.
PMID:
26045597
PMCID:
PMC4458806
DOI:
10.1182/blood-2015-03-635391
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center